VOV.VN - Vietnam has commenced construction of its first plasma-based biopharmaceutical production plant, located in the high ...

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

The global Cell Therapy Technologies market, valued at US$3.89 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

Microbial neutralization must constantly achieve a six-log reduction threshold of Geobacillus stearothermophilus and comply ...

ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for ...

BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE ...

The global Cell Therapy Technologies market, valued at US$3.89 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, reaching US$4.03 ...

Investing.com - European stock markets slipped lower Wednesday, with investors fretting following the release of ...

Repligen Corporation (RGEN), a life sciences company, on Monday announced the launch of its CTech SoloVPE PLUS System, an advanced ...

Repligen (RGEN) announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology ...

IMM-27M is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase II for Breast Cancer.

Recently, Viva Biotech's portfolio companies have new updates: TechnoDerma, VivaVision, Arthrosi, Apeiron Therapeutics and AceLink made solid progress in R&D; Full Circles published breakthrough ...